Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
- Written by PR Newswire
![]() |
- Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies
- Synaffix to receive up to $150m in upfront and milestone payments plus royalties
SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform...















